On 27 June 2016, orphan designation (EU/3/16/1673) was granted by the European Commission to FGK Representative Service Ltd, United Kingdom, for pyridoxine and L-pyroglutamic acid (the combination is also called metadoxine) for the treatment of fragile X syndrome.
Pyridoxine and L-pyroglutamic acid
|Disease / condition||
Treatment of fragile X syndrome
|Date of first decision||
|EU designation number||
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.